metylprednisolon hikma
edupharma, uab - metilprednizolonas - milteliai injekciniam tirpalui - 125 mg/5 ml; 1000 mg - methylprednisolone
metilprednisolona normon
adeofarma, uab - metilprednizolonas - milteliai ir tirpiklis injekciniam tirpalui - 40 mg - methylprednisolone
daploxin
medochemie ltd. - dapoksetino hidrochloridas - plėvele dengtos tabletės - 30 mg - dapoxetine
daploxin
medochemie ltd. - dapoksetino hidrochloridas - plėvele dengtos tabletės - 60 mg - dapoxetine
methylprednisolone sopharma
tbs pharma - metilprednizolonas - milteliai ir tirpiklis injekciniam tirpalui - 40 mg - methylprednisolone
cyclophosphamide accord
accord healthcare b.v. - ciklofosfamidas - milteliai injekciniam ar infuziniam tirpalui - 500 mg - cyclophosphamide
cyclophosphamide accord
accord healthcare b.v. - ciklofosfamidas - milteliai injekciniam ar infuziniam tirpalui - 1000 mg - cyclophosphamide
lisamethyle
adeofarma, uab - metilprednizolonas - milteliai ir tirpiklis injekciniam tirpalui - 40 mg - methylprednisolone
lyo-drol
edupharma, uab - metilprednizolonas - milteliai ir tirpiklis injekciniam tirpalui - 40 mg - methylprednisolone
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antinavikiniai vaistai - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.